Cannabis at The New York Times is not a formalized desk with a masthead of dedicated beat writers; it is a distributed topic covered across Business, Health, Politics, Metro, Styles, and Climate. That distinction shapes everything. You are not pitching a team — you are pitching individual reporters whose attention is split, whose editors are skeptical of promotional framing, and whose bylines define the beat week to week. This guide covers scope, roster verification, angles, and outreach for anyone working a The New York Times Cannabis reporters program.

The Times treats cannabis as a policy, business, and public-health story — rarely as a lifestyle or product story. High-probability coverage areas include federal rescheduling and DEA administrative process, hemp-derived THC and Farm Bill loopholes, state market rollouts and failures, social equity litigation, testing-lab reliability, multistate operator earnings and insolvency, and clinical research on cannabinoids and psychosis or hyperemesis. International legalization — Germany, Thailand, Canada — surfaces periodically, and Canada's post-legalization arc remains a favored cautionary frame. Low-probability: brand launches, celebrity endorsements, product reviews, "CBD for wellness" trend pieces. If your pitch cannot be defended as accountability journalism or documented trend reporting, it will not clear an editor.

Treat any The New York Times Cannabis reporters list as a starting hypothesis, not a verified map. Roster entries often reflect occasional bylines rather than sustained beat ownership — Ian Austen's cannabis work sits inside Canadian coverage, Emily Badger's inside urban policy, Aurelien Breeden's inside European affairs, John Carreyrou's inside investigative business. Before outreach, run a site:nytimes.com search filtered by cannabis keyword and the last 90 days, sort by date, and confirm the reporter still files on the topic under a current editor. Cross-check names against the outlet's staff pages and recent author bios. Build a tiered list: primary (three or more cannabis bylines in twelve months), secondary (one or two), and dormant (historic only — deprioritize).

The New York Times Cannabis journalists respond to documented tension: policy versus practice, revenue claims versus audited filings, patient access versus regulatory capture. Strongest angles: original datasets (licensing denial rates by county, lab-testing variance, tax-revenue shortfalls against projections), court records and FOIA materials, on-the-record named sources with direct knowledge, and access to contradicted parties. Weakest: market-size forecasts, commissioned surveys, and any figure you cannot source to a filing or public record. Frame the pitch as a story the reporter can own, with a one-line nut graf, two named sources, and a document offer in the first paragraph. Offer an exclusive; the Times rarely rewards widely pitched items.

Email only, to the individual reporter, subject line under eight words, body under 150 words. Never call the newsroom, never send embargoed material without prior agreement, and never bundle multiple stories. For The New York Times Cannabis journalists contacts, source addresses from staff pages, verified social profiles, or Muck Rack — never scraped lists — and confirm the reporter is still on the beat before sending. Disclose any client relationship in the first line. Expect silence as the default; one follow-up after five business days is acceptable, a third email is not. Keep a pitch log by reporter and topic to avoid repeat submissions.

• Reporter verified against a byline in the last 90 days
• Angle anchored to policy, health, or accountability — not promotion
• One-line nut graf and two named sources in the first paragraph
• Primary documents ready to send on request
• Exclusive offered; no simultaneous blast
• Client relationship disclosed up front
• No embargoed attachments unsolicited
• Logged in the tracker with date and outcome.